Epithelial Ovarian Cancer Drugs Market

SKU: DMPH3371 | Last Updated On: Aug 16 2022 | Available Formats

Epithelial Ovarian Cancer Drugs Market Expected to reach a high CAGR By 2029: DataM Intelligence

Epithelial Ovarian Cancer Drugs Market is segmented By Drug type (Carboplatin-taxon, Gemcitabine-Cisplatin, Bevacizumab, PARP inhibitors, Others), By Distribution channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Epithelial ovarian cancer drugs market size was valued at USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of % during the forecast period 2022-2029.

The most prevalent type of ovarian cancer is epithelial ovarian cancer, which originates in the tissue surrounding your ovaries. Fallopian tube cancer and primary peritoneal carcinoma are included. The most common type of ovarian cancer is high-grade serous ovarian cancer (HGSOC), which spreads quickly before being detected. Ovarian cancer tumors are removed with debulking surgery.

Key Highlights in the Report:

  • Adopting innovative combination medicines for treatment is a key driver of the expansion of the ovarian cancer drug market
  • The increasing research and developments are expected to drive the market growth in the forecast period
  • Carboplatin-taxon segment is expected to dominate the epithelial ovarian cancer drugs market growth
  • North America dominates the global epithelial ovarian cancer drugs market as the United States and Canada have well-structured and developed healthcare systems
  • Asia Pacific region is dominating a prominent share of revenues in the global market, and it is expected to grow at a high growth rate over the forecast period
  • The Europe region is anticipated to increase at a significant growth rate over the period forecast
  • The global epithelial ovarian cancer market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement scenario, pipeline analysis, pricing analysis, etc.

Market Dynamics

The factors influencing the global epithelial ovarian cancer drugs market are the increasing research and development and the growing prevalence of ovarian cancer.

Scientists are still looking into the genes that cause family ovarian cancer. This research is beginning to reveal how these genes typically function and how their disruption can result in cancer. This information is expected to develop novel medications to prevent and treat familial ovarian cancer. Better approaches to discovering high-risk genes and quantifying a woman’s ovarian cancer risk have emerged due to this research. A better knowledge of how genetic and hormonal factors (such as oral contraceptives) combine could lead to more effective prevention of ovarian cancer. Therapeutic research encompasses both evaluating the efficacy of already available methods and developing new treatment procedures.

For instance, targeted therapy is a relatively new cancer treatment method involving using medicines or other substances to detect and destroy cancer cells while causing minimal damage to healthy cells. Each type of targeted therapy operates differently, but they all assault the inner workings of cancer cells, the programming that distinguishes them from healthy cells. Bevacizumab (Avastin) is the most well-studied targeted therapy in ovarian cancer, but other comparable medications, such as pembrolizumab are also being investigated. Catumaxomab is a medication researched for persons with malignant ascites (fluid buildup in the abdomen [belly] caused by cancer cells). It operates by focusing on three main cell types, including tumor cells and T-cells, which are white blood cells.

Epithelial Ovarian Cancer Drugs Market Scope

Metrics

Details

Market CAGR

XY%

Segments Covered

By Drug Type, By Distributional Channels, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights about the market, Kindly get our sample brochure

Side effects associated with the treatment are expected to hamper the Epithelial Ovarian Cancer Drugs Market growth

Chemotherapy is particularly harmful because it targets all types of fast-growing cells.” Cancer cells are fast-growing cells, but so are all other cells in the body. Hair is one of them. When healthy cells are damaged, it leads to the adverse effects that women suffer throughout chemotherapy. Physical side effects of chemotherapy include fatigue, nausea, and numbness or tingling in the fingers and toes (neuropathy). Others like hair loss are more emotionally charged because they can significantly lower self-esteem.” After the initial treatment, most women lose their hair in two to three weeks. Usually, they lose everything. They also lose hair on their brows and pubic area. Hence, the increasing side effects associated with chemotherapy for ovarian cancer treatment are expected to hamper the market growth.

Impact of COVID-10 on the Epithelial Ovarian Cancer Drugs Industry:

The COVID-19 pandemic has sparked widespread panic among individuals and organizations worldwide since everyone anticipated herd immunity and/or vaccines that have yet to be licensed. Patients have been inconvenienced due to the disruption to healthcare centers that provide important health services. Health centers’ primary attention has changed to managing the COVID-19 pandemic during the pandemic. For instance, in Emilia-Romagna, one of the most afflicted Italian regions for COVID-19, Ovarian Cancer procedures were postponed or canceled. Furthermore, most hospitals canceled non-emergent and non-urgent patient visits due to the fear of disease spreading until a well-formalized plan to manage patient safety and limit infection risks was in place.

Detailed Segmentation Analysis of the Global Market

The global market is segmented into drug type, distributional channels, and region.

Based on Drug type, the market is divided into Carboplatin-taxon, Gemcitabine-Cisplatin, Bevacizumab, PARP inhibitors, and Others. Based on Distribution channels, it is further divided into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others.

Carboplatin + paclitaxel (commonly known as carbo-taxol) reduces tumors and relieves ovarian cancer symptoms. If the cancer is not metastatic (meaning it has progressed beyond the abdomen), carboplatin + paclitaxel is a typical treatment option. If cancer has spread to other body parts, carboplatin + paclitaxel may not be curative, but treatment can help prolong life and reduce symptoms. Carboplatin + paclitaxel is commonly administered in an outpatient infusion center, allowing the patient to return home. If someone is very unwell, carboplatin + paclitaxel may be given in the hospital.The typical treatment for advanced ovarian cancer is cisplatin 75 mg/m2 + paclitaxel 135 mg/m2 given over a 24-hour period. This schedule isn't suitable for use in an outpatient situation.

Carboplatin and paclitaxel are the cornerstones of ovarian cancer treatment, with carboplatin and paclitaxel being given to 95 percent of women diagnosed with the disease. The carboplatin-Taxol combination is well tolerated, with a clinical response rate of 50% to 80% and a median progression-free survival (PFS) of 13.6 to 19.3 months.

Geographical Analysis

According to the report analysis, the global market is classified into five major regions such as North America (United States, and Canada), Latin America (Mexico, Brazil, and Argentina), Europe (Germany, United Kingdom, Italy, Spain, London, Russia, and rest of the European countries), Asia Pacific (India, China, Japan, Argentina, Singapore, Malaysia, and Rest of the Asia countries), Middle East and Africa (Saudi Arabia, UAE, and South African Countries), and rest of the global countries.

Regional Share Insights Overview:

The North American region is expected to hold the largest market share in the global epithelial ovarian cancer drugs market. The growing prevalence of ovarian cancer and increasing research and development is expected to drive the market growth in this region.

According to the American Cancer Society estimates for ovarian cancer in the United States, in 2022, 19,880 women will be diagnosed with ovarian cancer for the first time. Ovarian cancer is expected to claim the lives of approximately 12,810 women. This cancer primarily affects women in their forties and fifties. About half of all women diagnosed with ovarian cancer are above 63. White women are more likely to have it than African-American women. Hence, the growing prevalence of ovarian cancer is expected to boost the market growth.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to the increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. 

Competitive Landscape and Major Companies Covered in the Global Market:

The global epithelial ovarian cancer drugs market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are GlaxoSmithKline plc, AstraZeneca, Roche, Boehringer Ingelheim GmbH, Millennium Pharmaceuticals, Inc, Amgen, Inc., ImmunoGen, Inc., Pharmacyclics, Inc., Bayer AG, Oasmia Pharmaceutical AB

Company Profile – GlaxoSmithKline plc

Overview: GSK plc, formerly GlaxoSmithKline plc, is a worldwide pharmaceutical business based in London, England, with corporate offices in Philadelphia, Pennsylvania. The company was founded in 2000.

Product Portfolio:

ZEJULA is a prescription medication used to treat the following conditions: Adultsults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer receive maintenance treatment. ZEJULA is taken if the malignancy has responded to platinum-based chemotherapy (full or partial response).

The global epithelial ovarian cancer drugs market report would provide an access to an approx. 45+market data table, 40+figures, and 180 pages.

Trending Topics

Gastrointestinal Cancer Drugs Market

Urothelial Cancer Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest